Navigation Links
First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference

PHILADELPHIA, March 5 /PRNewswire/ -- Cellvizio Inc., a leader in in vivo cellular imaging, announced today that the first live U.S. demonstration of its Cellvizio(R) GI technology will be conducted March 10, 2008, during the Johns Hopkins University School of Medicine's Eighth Annual Gastroenterology and Hepatology Viva La Vida Conference.

Cellvizio Inc. is the U.S. subsidiary of Paris-based Mauna Kea Technologies and develops and markets Cellvizio, a fundamentally new endoscopic imaging approach which could improve patient care by eliminating the need for unnecessary biopsies and could enhance the diagnosis of a broad range of diseases via in vivo cellular imaging.

The Cellvizio GI procedure will be performed at the Johns Hopkins Hospital in Baltimore during an endoscopy to assist with the diagnosis of Barrett's esophagus. It will be seen live via satellite by attendees of the conference, which is being held March 10-15 in San Juan, Puerto Rico. Gastroenterologists, surgeons and other healthcare professionals with an interest in gastroenterology and hepatology are participating in the program.

"Cellvizio allows physicians to view live tissue inside the body at the cellular level in real-time with a miniaturized microscope threaded through an endoscope and has the potential to benefit patients by reducing invasiveness while speeding up diagnosis," explained Sacha Loiseau, president, CEO and founder of Mauna Kea Technologies. "For example, a current diagnosis of Barrett's esophagus may require 10 to 50 biopsies to be taken and analyzed by a pathologist off line. The use of Cellvizio during this procedure could help reduce this number significantly by allowing physicians to avoid unnecessary biopsies."

Cellvizio GI is commercially available in Europe and in the United States.

About Mauna Kea Technologies:

Mauna Kea Technologies leads the growing in vivo cellular imaging market enabling physicians to visualize, diagnose and treat pathologies that can not be seen using other imaging techniques. Mauna Kea Technologies' flagship Cellvizio system provides microscopic visualization of mucosal tissue and promises to improve clinical outcomes by increasing the diagnostic yield of existing endoscopic procedures. With over 1000 Cellvizio procedures completed to date, Mauna Kea Technologies is currently focused on the gastroenterology and pulmonology markets. The company plans to expand into other markets in the future. The company also has a distribution agreement with Leica Microsystems to sell products for the Small Animal Imaging market in Europe, the U.S. and Japan. For more information about Mauna Kea Technologies:

About The Conference:

The Eighth Annual Gastroenterology and Hepatology: Viva la Vida conference will provide, through formal lectures, followed by questions and answers, a discussion of various disorders, with an emphasis on recent developments. Participants will be updated on the latest management of GI cancers and approaches for the difficult GI bleeder. Endoscopic imaging and therapies will be demonstrated live from the Johns Hopkins Hospital and University of Puerto Rico by renowned international experts.
For more information:


Erich Sandoval

Lazar Partners

Tel. 212-867-1773


SOURCE Cellvizio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
2. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant
3. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
4. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
5. BSPs New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study
6. First Complete Career Service for Life-Science Professionals
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Biopure Announces 2008 First Quarter Financial Results
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
11. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
Post Your Comments:
(Date:12/1/2015)... -- Cepheid (Nasdaq: CPHD ) today announced that, ... Healthcare Conference in New York City ... outlook for the fourth quarter of 2015 and initiating ... term business model expectations. John Bishop , ... be the fastest growing company of the major market ...
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... MIAMI (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group ... new clinics in the cities of Arica and Iquique in northern Chile. The facilities are ... clinics offer the most advanced protocols and techniques in stem cell medicine to patients from ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, a ... chemistry professor Jan Halámek, is taking crime scene ...   -->   ... --> --> ... have discovered a straightforward concept for identifying whether ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
Breaking Biology News(10 mins):